Clearside Biomedical, Inc

clearsidebio.com

The filing excerpts provided for CLSDQ (accession 000095017025046134, filed 2025-03-27) contain only boilerplate SEC cover-page text and do not include any substantive business description, financial data, segment information, or operational details sufficient to construct a grounded company summary.

Peers: TherapeuticsMD Inc Anebulo Pharmaceuticals Inc Aquestive Therapeutics Inc Hyperion DeFi Inc Johnson & Johnson Longboard Pharmaceuticals, Inc. Medicine Man Technologies, Inc. SCYNEXIS Inc

Source: SEC 10-K, filed 2025-03-27

Dive deeper

Financial Snapshot

Revenue

TTM

$3.329M

Gross Margin

TTM

85.17%

Net Income

TTM

-$26.00M

Current Assets

2025 Q3

$8.254M

Current Liabilities

2025 Q3

$2.770M

Current Ratio

2025 Q3

297.98%

Total Assets

2025 Q3

$11.64M

Total Liabilities

2025 Q3

$65.59M

Book Value

2025 Q3

-53.95M

Cash

2025 Q3

$6.801M

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

-$16.27M

Stock Price

Market Cap: $580 Thousand